Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China

被引:36
作者
Li, Shouwei [2 ,3 ]
Yan, Changxiang [2 ]
Huang, Lei [1 ]
Qiu, Xiaoguang [1 ]
Wang, Zhongcheng [3 ]
Jiang, Tao [1 ,3 ]
机构
[1] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing 100050, Peoples R China
[2] Capital Med Univ, Beijing Sanbo Brain Hosp, Dept Neurosurg, Beijing 100050, Peoples R China
[3] Beijing Neurosurg Inst, Beijing, Peoples R China
关键词
anaplastic oligodendroglial tumor; IDH1; mutation; LOH 1p and 19q; MGMT; prognostic factor; EUROPEAN ORGANIZATION; CHROMOSOME; 1P; 19Q STATUS; MGMT GENE; CHEMOTHERAPY; TEMOZOLOMIDE; EXPRESSION; SURVIVAL; P53; OLIGOASTROCYTOMAS;
D O I
10.1093/neuonc/nor185
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The increased chemosensitivity of oligodendroglial tumors has been associated with loss of heterozygosity (LOH) on chromosomes 1p and 19q. Other clinical and molecular factors have also been identified as being prognostic and predictive for treatment outcome. Seventy-seven patients with anaplastic oligodendroglioma (AO) or anaplastic oligoastrocytoma (AOA), treated in Beijing Tiantan Hospital from 2006 through 2008, were reviewed. LOH 1p, LOH 19q, IDH1 mutation, O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation, and protein expression level of MGMT, P53, EGFR, and Ki-67 were evaluated. Age at diagnosis, LOH 1p and 19q, IDH1 mutation, P53 expression level, reoperation when progression, and adjuvant chemotherapy were statistically significant factors for overall survival (OS) in univariate analysis. Further multivariate analysis showed that age at diagnosis (P = .010), LOH 1p and 19q (P = .016), IDH1 mutation (P = .011), and reoperation after progression (P = .048) were independent predictors for longer survival in these patients. Nonrandom associations were found between LOH 1p and LOH 19q, MGMT promoter methylation and LOH 1p or 19q, IDH1 mutation and LOH 1p and 19q, IDH1 mutation and MGMT promoter methylation, whereas mutual exclusion was found between MGMT promoter methylation and MGMT expression level. The present study confirmed that age at diagnosis, LOH 1p and 19q, IDH1 mutation, and reoperation after progression were independent significant prognostic factors for patients with anaplastic oligodendroglial tumors. Inter-relationship between LOH 1p, LOH 19q, IDH1 mutation, MGMT promoter methylation, and MGMT expression level were also revealed. Future clinical trials for AO and AOA should consider the molecular alterations of patients.
引用
收藏
页码:109 / 116
页数:8
相关论文
共 29 条
  • [21] Influence of Histological Subtype on Survival after Combined Therapy of Surgery and Radiation in WHO Grade 3 Glioma
    Shirai, Katsuyuki
    Suzuki, Yoshiyuki
    Okamoto, Masahiko
    Wakatsuki, Masaru
    Noda, Shin-Ei
    Takahashi, Takeo
    Ishiuchi, Shogo
    Hasegawa, Masatoshi
    Nakazato, Yoichi
    Nakano, Takashi
    [J]. JOURNAL OF RADIATION RESEARCH, 2010, 51 (05) : 589 - 594
  • [22] Soffietti R, 2004, EXPERT OPIN PHARMACO, V5, P295, DOI 10.1517/14656566.5.2.295
  • [23] Ueki K, 2002, CLIN CANCER RES, V8, P196
  • [24] Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial
    van den Bent, Martin J.
    Carpentier, Antoine F.
    Brandes, Alba A.
    Sanson, Marc
    Taphoorn, Martin J. B.
    Bernsen, Hans J. J. A.
    Frenay, Marc
    Tijssen, Cees C.
    Grisold, Wolfgang
    Sipos, Laslo
    Haaxma-Reiche, Hanny
    Kros, Johannes M.
    van Kouwenhoven, Mathilde C. M.
    Vecht, Charles J.
    Allgeier, Anouk
    Lacombe, Denis
    Gorlia, Thierry
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2715 - 2722
  • [25] IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
    van den Bent, Martin J.
    Dubbink, Hendrikus J.
    Marie, Yannick
    Brandes, Alba A.
    Taphoorn, Martin J. B.
    Wesseling, Pieter
    Frenay, Marc
    Tijssen, Cees C.
    Lacombe, Denis
    Idbaih, Ahmed
    van Marion, Ronald
    Kros, Johan M.
    Dinjens, Winand N. M.
    Gorlia, Thierry
    Sanson, Marc
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (05) : 1597 - 1604
  • [26] Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131
    Vogelbaum, Michael A.
    Berkey, Brian
    Peereboom, David
    Macdonald, David
    Giannini, Caterina
    Suh, John H.
    Jenkins, Robert
    Herman, James
    Brown, Paul
    Blumenthal, Deborah T.
    Biggs, Christopher
    Schultz, Christopher
    Mehta, Minesh
    [J]. NEURO-ONCOLOGY, 2009, 11 (02) : 167 - 175
  • [27] IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas
    Watanabe, Takuya
    Nobusawa, Sumihito
    Kleihues, Paul
    Ohgaki, Hiroko
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2009, 174 (04) : 1149 - 1153
  • [28] Yakut T, 2007, ONCOL REP, V17, P1037
  • [29] Factors affecting prognosis of patients with intracranial anaplastic oligodendrogliomas: a single institutional review of 70 patients
    Yang, Liu-song
    Huang, Feng-ping
    Zheng, Kang
    Zhang, Hai-shi
    Zhou, Xiang
    Bao, Xu-hui
    Zheng, Jia-jun
    Chang, Chuan
    Zhou, Liang-fu
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2010, 100 (01) : 113 - 120